CHMA - Chiasma Inc. Appears Materially Undervalued If Mycapssa's NDA Is Approved By The FDA On June 26
If Chiasma Inc.'s (CHMA) Mycapssa is approved as an orphan drug by the FDA on or around June 26, 2020, as anticipated, as the first and only FDA approved oral therapy (or pill) to treat acromegaly, a rare condition affecting 8,000 patients in the US, our analysis concludes Chiasma Inc.'s share price at ~$5.50 would be materially undervalued. This is primarily because 90% of patients who tried Mycapssa voluntarily opted to continue with Mycapssa when given the option of going back to 1 of the 4 injectable therapies they used before they participated in clinical